PFN-55154 |
GINSENG & POLEN CON JALEA REAL VESA Solución Oral |
2023-04-09 |
|
Vesa Laboratorios |
República Popular China
|
Vesa Laboratorios |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PFN-52946 |
GINSENG CON JALEA REAL DRAGON Solución oral |
2027-01-21 |
|
Vesa Laboratorios |
República de China
|
Vesa Laboratorios |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-39535 |
AMPICILINA IDA 500 mg liofilizado para uso parenteral |
2012-10-02 |
|
Ida |
Holanda (Países Bajos)
|
Ida |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-39200 |
FILGRASTIM Harbin 300 mcg solucion inyectable |
2012-07-25 |
|
Harbin Pharmaceutical Group Bioengineering, Co Ltd. |
República de China
|
Diagnopharm, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-39273 |
INTERFERON ALFA 2 B Harbin Pharmaceutical 3MUI Liofilizado para Uso* |
2012-08-02 |
|
Harbin Pharmaceutical Group Bioengineering, Co Ltd. |
República de China
|
Diagnopharm, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-38525 |
PENICILINA SODICA Harbin 1 millon de UI Liofilizado para Uso * |
2012-03-05 |
|
Harbin Pharmaceutical Group Co., Ltd Gral Pharm Factory |
República de China
|
Diagnopharm, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-39013 |
CEFEPIMA DICLORHIDRATO Harbin 1 g Liofilizado para Uso Parenteral |
2012-06-25 |
|
Harbin Pharmaceutical Group Co., Ltd Gral Pharm Factory |
República de China
|
Diagnopharm, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-39189 |
CEFOTAXIMA SODICA Diagnopharm 1 g Liofilizado para Uso Parenteral |
2012-07-24 |
|
Diagnopharm, S.A. |
República de China
|
Diagnopharm, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-41543 |
AMOXICILINA Harbin Pharmaceutical 0.5 g cápsula |
2013-10-06 |
|
Harbin Pharmaceutical Group Co., Ltd Gral Pharm Factory |
República de China
|
Diagnopharm, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-41855 |
AMOXICILINA SODICA Y CLAVULANATO POTASICO Harbin Pharmaceutical 1.2 g liofilizado para uso parenteral |
2013-11-11 |
|
Harbin Pharmaceutical Group Co., Ltd Gral Pharm Factory |
República de China
|
Diagnopharm, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|